Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Decisional tools have demonstrated their importance in informing manufacturing and commercial decisions in the monoclonal antibody domain (mAb). Recent approved therapies in regenerative medicine have shown great clinical benefits to patients. This study investigates what are the decisional tools available and what issues and gaps have been raised for their use in regenerative medicine. We systematically searched the literature to identify publications on decision-support tools relevant to tissue engineering, cell and gene therapy, with the aim of identifying gaps for future decisional tool development. Identified papers have addressed key decisions in manufacturing and product development challenges in cell therapies. Our review has identified a limited number of decisional tools. There is ample space for expansion especially with regard to autologous cell therapies, tissue engineering and gene therapies.

Original publication

DOI

10.2196/12448

Type

Journal article

Journal

Journal of Medical Internet Research

Publisher

Journal of Medical Internet Research

Publication Date

20/11/2018